Marleen Van den Horst
Provided by Marleen Van den Horst
* IP & technology
* Life sciences, Pharma & regulatory
* Patents and technology
Marleen van den Horst is partner in the IP and Technology practice group and heads the industry group Healthcare and Life Sciences. Marleen has more than 25 years of experience in conducting complex, cross-border proceedings on intellectual property. Specialised in patent law, she handles cases involving mechanical engineering, electrical engineering, chemistry and life sciences. From ship shutters, electronic Braille cells, floating solar panels, telecoms UMTS and LTE standard essential patents to medical equipment and pharmaceuticals. Marleen has achieved international recognition in the field of Life Sciences. In recent years, she has litigated and advised on patent and administrative litigation concerning, among other things, drugs whose active ingredients are ciclosporin, (es)omeprazole alendronate, escitalopram, modafinil, tramadol/paracetamol, glatiramer acetate, trastuzumab, zoledronate, rivastigmine, lenalidomide, ezetimibe+simvastatin, dasatinib, pemetrexed and sitagliptin as well as on CRISPR-Cas9 technology. Aside from litigation, Marleen also assists clients in negotiating and drawing up licences, technology transfers and distribution and cooperation agreements.
* Board member of the NeoKidney Foundation for the realisation of a wearable artificial kidney.
* Member of several professional organisations and trade associations, such as EPLAW,
AIPPI, LES, VF&R and VIEPA.
Marleen Van den Horst is particularly popular with clients from the pharmaceutical industry for advice on the IP aspects of product launches, including patent infringement and invalidity actions. In addition, she represents clients in patent enforcement proceedings.
"She goes straight to the point and is very practical."